10x Genomics Inc (NASDAQ:TXG) shares, rose in value on Thursday, March 27, with the stock price down by -1.77% to the previous day’s close as strong demand from buyers drove the stock to $9.41.
Actively observing the price movement in the last trading, the stock closed the session at $9.58, falling within a range of $9.31 and $9.65. The value of beta (5-year monthly) was 1.928. Referring to stock’s 52-week performance, its high was $38.49, and the low was $9.27. On the whole, TXG has fluctuated by -19.23% over the past month.
With the market capitalization of 10x Genomics Inc currently standing at about $1.15 billion, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Feb-11.
Projections by analysts suggest varying estimates for the company’s quarterly revenue. Analysts have estimated the company’s revenue for the quarter at 612.79M, with a low estimate of 121.3M and a high estimate of 147.9M. Wall Street analysts also predicted that the company’s y-o-y revenues would reach 132.8M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that TXG’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of TXG currently trading nearly -9.81% and -23.45% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 35.36, while the 7-day volatility ratio is showing 5.59% which for the 30-day chart, stands at 7.06%. Furthermore, 10x Genomics Inc (TXG)’s beta value is 1.99, and its average true range (ATR) is 0.72.
A comparison of 10x Genomics Inc (TXG) with its peers suggests the former has fared considerably weaker in the market. TXG showed an intraday change of -1.77% in last session, and over the past year, it shrunk by -74.08%%.
Data on historical trading for 10x Genomics Inc (NASDAQ:TXG) indicates that the trading volumes over the past 10 days have averaged 3.05 and over the past 3 months, they’ve averaged 2.76 million. According to company’s latest data on outstanding shares, there are 108.24 million shares outstanding.
Nearly 17.59% of 10x Genomics Inc’s shares belong to company insiders and institutional investors own 79.43% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 12.08 million shares as on 2025-03-14, resulting in a short ratio of 3.63. According to the data, the short interest in 10x Genomics Inc (TXG) stood at 1289.00 of shares outstanding as of 2025-03-14; the number of short shares registered in 2025-02-14 reached 11.32 million. The stock has fallen by -34.47% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the TXG stock heading into the next quarter.
